These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29451049)

  • 41. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
    Carmel AS; Shieh A; Bang H; Bockman RS
    Osteoporos Int; 2012 Oct; 23(10):2479-87. PubMed ID: 22237813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis.
    Feng Z; Zeng S; Wang Y; Zheng Z; Chen Z
    PLoS One; 2013; 8(12):e80890. PubMed ID: 24324644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AI-related BMD variation in actual practice conditions: A prospective cohort study.
    Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
    Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone Mineral Density Response to Long-Term Bisphosphonate Treatment and Discontinuation in a Real-World Clinical Service.
    Powell DE; Evans SF; Rakieh C
    Endocr Pract; 2023 Aug; 29(8):601-605. PubMed ID: 37149036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
    Lim JS; Jin SH; Kim SB; Lee JI
    J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Bisphosphonates and Calcium plus Vitamin-D Supplements on Cognitive Function in Postmenopausal Osteoporosis§.
    Safer U; Safer VB; Demir SO; Yanikoglu I
    Endocr Metab Immune Disord Drug Targets; 2016; 16(1):56-60. PubMed ID: 27026340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New spine and non-spine fractures in 871 women/year treated with oral pamidronate plus calcium and vitamin D supplements].
    Man Z; Otero AB
    Medicina (B Aires); 1997; 57 Suppl 1():32-6. PubMed ID: 9567352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
    Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
    Naylor KE; McCloskey EV; Jacques RM; Peel NFA; Paggiosi MA; Gossiel F; Walsh JS; Eastell R
    Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased Serum 25(OH)D
    Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
    Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study.
    Lu C; Chen Y; Zhang B; Chen Y; Bai F; Chen D
    Clin Interv Aging; 2017; 12():1717-1723. PubMed ID: 29066877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
    Kharroubi A; Saba E; Smoom R; Bader K; Darwish H
    Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats.
    Mastaglia SR; Pellegrini GG; Mandalunis PM; Gonzales Chaves MM; Friedman SM; Zeni SN
    Bone; 2006 Oct; 39(4):837-44. PubMed ID: 16765665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.